Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Epigenetic enzyme mutations as mediators of anti-cancer drug resistance.

Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy - 1 Mar 2022

Chen Sihong, Zhao Yingxi, Liu Shougeng, Zhang Jiayu, Assaraf Yehuda G, Cui Wei, Wang Lihui

Abstract excerpt

Despite the rapid advancement in the introduction of new drugs for cancer therapy, the frequent emergence of drug resistance leads to disease progression or tumor recurrence resulting in dismal prognosis. Given that genetic mutations are thought to be important drivers of anti-cancer drug resistance, it is of paramount importance to pin-point mutant genes that mediate drug resistance and elucidate the underlying...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Epigenesis, Genetic

Share to Mutation

Share to Neoplasms

Source

Identifiers

PMID: 35219075
DOI: 10.1016/j.drup.2022.100821

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Epigenetic enzyme mutations as mediators of anti-cancer drug resistance.PMID 35219075Read ↗

An update on DOT1LWT/MUT modulators as a promising anticancer strategy.Semantic proximity Read ↗

Novel inhibitors of the histone methyltransferase DOT1L show potent antileukemic activity in patient-derived xenograftsSemantic proximity Read ↗

PARP1-DOT1L transcription axis drives acquired resistance to PARP inhibitor in ovarian cancerSemantic proximity Read ↗

Molecular pathways: protein methyltransferases in cancer.Semantic proximity Read ↗

Regulation of cisplatin resistance in lung cancer by epigenetic mechanismsSemantic proximity Read ↗

Rapid generation of drug-resistance alleles at endogenous loci using CRISPR-Cas9 indel mutagenesis.Semantic proximity Read ↗

Mechanisms of Pinometostat (EPZ-5676) Treatment–Emergent Resistance in MLL -Rearranged LeukemiaSemantic proximity Read ↗

Targeting DNA Damage Response-Mediated Resistance in Non-Small Cell Lung Cancer: From Mechanistic Insights to Drug DevelopmentSemantic proximity Read ↗

Role of somatic cancer mutations in human protein lysine methyltransferases.Semantic proximity Read ↗

Somatic alterations and dysregulation of epigenetic modifiers in cancers.Semantic proximity Read ↗

Designing Effective Protein Lysine and Arginine Methyltransferase Inhibitors for Chemotherapeutic TargetingSemantic proximity Read ↗

The histone methyltransferase DOT1L is required for proper DNA damage response, DNA repair, and modulates chemotherapy responsivenessSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.